Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

31 mars 2022 12h00 HE | Source: ORPHAZYME A/S

Proposal for a statutory restructuring plan

Orphazyme A/S in restructuringCompany announcementNo. 15/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 31, 2022 – Orphazyme A/S in...
29 mars 2022 07h15 HE | Source: ORPHAZYME A/S

Updated Financial Calendar for 2022

Orphazyme A/S in restructuringCompany announcementNo. 14/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 29, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH)...
22 mars 2022 06h54 HE | Source: ORPHAZYME A/S

Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C

Orphazyme A/SCompany announcementNo. 13/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Decision to withdraw the European Marketing Authorisation Application comes ahead of...
21 mars 2022 17h44 HE | Source: ORPHAZYME A/S

Orphazyme A/S has filed for voluntary delisting of ADSs

Orphazyme A/SCompany announcementNo. 12/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 21, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
18 mars 2022 06h40 HE | Source: ORPHAZYME A/S

Notice of in-court restructuring proceedings of Orphazyme A/S

Orphazyme A/SCompany announcementNo. 11/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 18, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
10 mars 2022 16h05 HE | Source: ORPHAZYME A/S

Commencement of in-court restructuring of Orphazyme A/S

Orphazyme A/SCompany announcementNo. 10/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Will institute a reduction of approximately 50% of current work forceIntends to...
03 mars 2022 03h35 HE | Source: ORPHAZYME A/S

Updated Financial Calender for 2022

Orphazyme A/SCompany announcementNo. 09/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 3, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
28 févr. 2022 02h25 HE | Source: ORPHAZYME A/S

Anders Vadsholt takes over as CEO of Orphazyme

Company announcementNo. 08/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 28, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
23 févr. 2022 16h05 HE | Source: ORPHAZYME A/S

Orphazyme announces update on regulatory review of arimoclomol in the European Union

Orphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US))...
18 févr. 2022 16h01 HE | Source: ORPHAZYME A/S

Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program

Orphazyme A/SCompany announcementNo. 06/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 18, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a...

Page précédente

Page suivante